128238-43-7

Basic information

• Product Name: 4-(TRIFLUOROACETYLAMINO)-1-BUTANOL
• Synonyms: 4-(TRIFLUOROACETYLAMINO)-1-BUTANOL;TFA-ABU(4)-OL;TFA-NH-(CH2)4-OH;N-TRIFLUOROACETYL-DELTA-AMINO-N-BUTYL ALCOHOL;N-TRIFLUOROACETYL-4-AMINO-1-BUTANOL;N-(4-HYDROXYBUTYL)TRIFLUOROACETAMIDE;4-(trifluoroacetamido)-1-butanol
• CAS NO: 128238-43-7
• Molecular Formula: C₆H₁₀F₃NO₂
• Molecular Weight: 185.14
• Mol File: 128238-43-7.mol

Chemical Properties

• Boiling Point: 257.5°C at 760 mmHg
• Flash Point: 109.5°C
• Appearance: /
• Density: 1.262 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.00216mmHg at 25°C
• Refractive Index: n20/D 1.413
• PKA: 11.30±0.46(Predicted)
• BRN: 6644043
• CAS DataBase Reference: 4-(TRIFLUOROACETYLAMINO)-1-BUTANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROACETYLAMINO)-1-BUTANOL(128238-43-7)
• EPA Substance Registry System: 4-(TRIFLUOROACETYLAMINO)-1-BUTANOL(128238-43-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 128238-43-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H10F3NO2/c7-6(8,9)5(12)10-3-1-2-4-11/h11H,1-4H2,(H,10,12)

Upstream product

• 13325-10-5 4-Aminobutanol 
• 407-25-0 trifluoroacetic anhydride 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 1094764-71-2 O-(dibenzyloxyphosphoryl)-4-trifluoroacetamido-1-butanol 
• 1333028-07-1 methyl 4-[(1-azido-4-trifluoroacetamidobutoxy)methyl]benzoate 
• 663600-58-6 4-[(4,4'-dimethoxytrityl)oxy]butanamine 
• 32548-24-6 1,2,5,6,7,8-hexahydro-3H-pyrrolizin-3-one 
• 876746-11-1 C₃₃H₄₁F₃NO₇P 

Relevant articles and documents

Rapid Synthesis of Bicyclic N-Heterocyclic Cores from N-Terminal α,β-Unsaturated Diazoketones

A method for the synthesis of bicyclic N-heterocyclic cores from N-terminal α,β-unsaturated diazoketones has been developed. The transformation involves three sequential steps that include N-deprotection, an intramolecular aza-Michael, and a photochemical Wolff rearrangement as a one-pot protocol. By using this strategy, a series of substituted bicyclic N-heterocycles, particularly, indolizidines and pyrrolizidines, were synthesize in good yields.

Naphthalene diimide-polyamine hybrids as antiproliferative agents: Focus on the architecture of the polyamine chains

Naphthalene diimides (NDIs) have been widely used as scaffold to design DNA-directed agents able to target peculiar DNA secondary arrangements endowed with relevant biochemical roles. Recently, we have reported disubstituted linear- and macrocyclic-NDIs that bind telomeric and non-telomeric G-quadruplex with high degree of affinity and selectivity. Herein, the synthesis, biological evaluation and molecular modelling studies of a series of asymmetrically substituted NDIs are reported. Among these, compound 9 emerges as the most interesting of the series being able to bind telomeric G-quadruplex (ΔTm = 29 °C at 2.5 μM), to inhibit the activity of DNA processing enzymes, such as topoisomerase II and TAQ-polymerase, and to exert antiproliferative effects in the NCI panel of cancer cell lines with GI50values in the micro-to nanomolar concentration range (i.e. SR cell line, GI50= 76 nM). Molecular mechanisms of cell death have been investigated and molecular modelling studies have been performed in order to shed light on the antiproliferative and DNA-recognition processes.

Remote Regioselective Radical C-H Functionalization of Unactivated C-H Bonds in Amides: The Synthesis of gem-Difluoroalkenes

The site-selective functionalization of unactivated aliphatic amines is an attractive and challenging synthetic approach. We herein report a general strategy for the remote site-selective functionalization of unactivated C(sp3)-H bonds in amides by photogenerated amidyl radicals to form gem-difluoroalkenes with trifluoromethyl-substituted alkenes. The site selectivity is controlled by a 1,5-hydrogen atom transfer (HAT) process of the amide. This photocatalyzed transformation shows both chemo- and site-selectivity, facilitating the formation of a secondary, tertiary, or quaternary carbon center.

Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming

A series of hybrid compounds was designed to target histone deacetylases and ds-/G-quadruplex DNAs by merging structural features deriving from Scriptaid and compound 1. Compound 6 binds different DNA arrangements, inhibits HDACs both in vitro and in cells, and is able to induce a reduction of cell proliferation. Moreover, compound 6 displays cell phenotype-reprogramming properties since it prevents the epithelial to mesenchymal transition in cancer cells, inducing a less aggressive and migratory phenotype, which is one of the goals of present innovative strategies in cancer therapies.

Micro-RMA inhibitor

The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

REDUCTIVE RELEASE PROBES CONTAINING A CHEMOSELECTIVELY CLEAVABLE ALPHA-AZIDOETHER LINKER AND METHODS OF USE THEREOF

Probes comprising one or more selectively cleavable α-azidoether moieties are provided; and linkers comprising the one or more selectively cleavable α-azidoether moieties. The α-azidoether moiety will undergo a Staudinger reaction with a suitable reducing agent, resulting in cleavage. The probes find use in a variety of detection assays, e.g. specific polynucleotide binding assays, polypeptide binding assays, etc. The cleavable linkers are suitable for synthetic reactions, e.g. to prepare probes of the invention; in the synthesis of cleavable peptide conjugates; and the like.

INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH

Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5'-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP- galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.

Potent ligands for prokaryotic UDP-galactopyranose mutase that exploit an enzyme subsite

UDP-Galactopyranose mutase (UGM or Glf), which catalyzes the interconversion of UDP-galactopyranose and UDP-galactofuranose, is implicated in the viability and virulence of multiple pathogenic microorganisms. Here we report the synthesis of high-affinity ligands for UGM homologues from Klebsiella pneumoniae and Mycobacterium tuberculosis. The potency of these compounds stems from their ability to access both the substrate binding pocket and an adjacent site.

Azabicycloalkane derivatives and therapeutic uses thereof

The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.

Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5ht2a antagonists

The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.